Free Access
| Issue |
Biologie Aujourd’hui
Volume 213, Number 1-2, 2019
|
|
|---|---|---|
| Page(s) | 59 - 64 | |
| DOI | https://doi.org/10.1051/jbio/2019021 | |
| Published online | 5 juillet 2019 | |
- Alder Biopharmaceuticals, Inc. (2017). A multicenter assessment of ALD403 in frequent episodic migraine. Available from https://clinicaltrials.gov/ct2/show/NCT02559895. [Google Scholar]
- Buettner, C., Nir, R.R., Bertisch, S.M., Bernstein, C., Schain, A., Mittleman, M.A., Burstein, R. (2015). Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Ann Neurol, 78, 970-981. [CrossRef] [PubMed] [Google Scholar]
- Cady, R.K., Mathew, N., Diener, H.C., Hu, P., Haas, M., Novak, G.P., Study Group. (2009). Evaluation of carisbamate for the treatment of migraine in a randomized, double-blind trial. Headache, 49, 216-226. [CrossRef] [PubMed] [Google Scholar]
- Cao, Y., Zheng, O.J. (2014). Tonabersat for migraine prophylaxis: A systematic review. Pain Physician, 17, 1-8. [Google Scholar]
- Caproni, S., Corbelli, I., Pini, L.A., Cupini, M.L., Calabresi, P., Sarchielli, P. (2011). Migraine preventive drug-induced weight gain may be mediated by effects on hypothalamic peptides: The results of a pilot study. Cephalalgia, 31, 543-549. [CrossRef] [PubMed] [Google Scholar]
- Chabi, A., Zhang, Y., Jackson, S., Cady, R., Lines, C., Herring, W.J., Connor, K.M., Michelson, D. (2015). Randomized controlled trial of the orexin receptor antagonist filorexant for migraine prophylaxis. Cephalalgia, 35, 379-388. [CrossRef] [PubMed] [Google Scholar]
- Eli Lilly and Company. (2017). Evaluation of LY2951742 in the prevention of episodic migraine – the EVOLVE-1 study. Available from https://clinicaltrials.gov/ct2/show/NCT02614183. [Google Scholar]
- Goadsby, P.J., Reuter, U., Hallström, Y., Broessner, G., Bonner, J.H., Zhang, F., Sapra, S., Picard, H., Mikol, D.D., Lenz, R.A. (2017). A controlled trial of erenumab for episodic migraine. N Engl J Med, 377, 2123-2132. [Google Scholar]
- Hoffmann, J., Supronsinchai, W., Akerman, S., Andreou, A.P., Winrow, C.J., Renger, J., Hargreaves, R., Goadsby, P.J. (2015). Evidence for orexinergic mechanisms in migraine. Neurobiol Dis, 74, 137-143. [CrossRef] [PubMed] [Google Scholar]
- Karsan, N., Gonzales, E.B., Dussor, G. (2018). Targeted acid-sensing ion channel therapies for migraine. Neurotherapeutics, 15, 402-414. [Google Scholar]
- Kwok, Y.H., Swift, J.E., Gazerani, P., Rolan, P. (2016). A double-blind, randomized, placebo-controlled pilot trial to determine the efficacy and safety of ibudilast, a potential glial attenuator, in chronic migraine. J Pain Res, 9, 889-907. [Google Scholar]
- Lambru, G., Andreou, A.P., Guglielmetti, M., Martelletti, P. (2018). Emerging drugs for migraine treatment: An update. Expert Opin Emerg Drugs, PMID 30484333. [Google Scholar]
- Olesen, J., Diener, H.C., Husstedt, I.W., Goadsby, P.J., Hall, D., Meier, U., Pollentier, S., Lesko, L.M., BIBN 4096 BS Clinical Proof of Concept Study Group. (2004). Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med, 350, 1104-1110. [Google Scholar]
- Pradhan, A.A., Bertels, Z., Akerman, S. (2018). Targeted nitric oxide synthase inhibitors for migraine. Neurotherapeutics, 15, 391-401. [Google Scholar]
- Schwedt, T.J., Vargas, B. (2015). Neurostimulation for treatment of migraine and cluster headache. Pain Med, 16, 1827-1834. [CrossRef] [PubMed] [Google Scholar]
- Teva Branded Pharmaceutical Products, R&D Inc. (2017). Efficacy and safety of 2 dose regimens of TEV-48125 versus placebo for the preventive treatment of episodic migraine. Available from https://clinicaltrials.gov/ct2/show/NCT02629861. [Google Scholar]
- Tzabazis, A., Kori, S., Mechanic, J., Miller, J., Pascual, C., Manering, N., Carson, D., Klukinov, M., Spierings, E., Jacobs, D., Cuellar, J., Frey, W.H., 2nd, Hanson, L., Angst, M., Yeomans, D.C. (2017). Oxytocin and migraine headache. Headache, 57(Suppl 2), 64-75. [CrossRef] [PubMed] [Google Scholar]
- Vila-Pueyo, M. (2018). Targeted 5-HT1F therapies for migraine. Neurotherapeutics, 15, 291-303. [Google Scholar]
- Zagami, A.S., Edvinsson, L., Goadsby, P.J. (2014). Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol, 1, 1036-1040. [CrossRef] [PubMed] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.